Brief: Nuwellis’ Distribution Partner, SeaStar, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device
22/02/2024 14:45
Feb 22 (Reuters) - SeaStar Medical Holding Corp ICU.O :
* NUWELLIS’ DISTRIBUTION PARTNER, SEASTAR MEDICAL, RECEIVES
FDA
HUMANITARIAN DEVICE EXEMPTION FOR PEDIATRIC SELECTIVE
CYTOPHERETIC DEVICE QUELIMMUNE™
* NUWELLIS - TO BEGIN COMMERCIAL LAUNCH ACTIVITIES AT
TARGETED
MEDICAL CENTERS, WITH FURTHER COMMERCIAL EXPANSION EXPECTED
LATER IN FIRST HALF OF 2024
Source text for Eikon: ID:nGNX6tMWvX
Further company coverage: ICU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SeaStar Medical Holding
See all newsBrief: FDA Grants Seastar Medical Breakthrough Device Designation For Its Scd Therapy For The Treatment Of Hyperinflammation In Adult Patients With Sepsis Or A Septic Condition
SeaStar Medical Holding Corp reports results for the quarter ended June 30 - Earnings Summary
SeaStar Medical Q2 revenue jumps 82% on QUELIMMUNE demand
Brief: SeaStar Medical Q2 EPS USD -0.91
SeaStar Medical Holding Corp expected to post a loss of 97 cents a share - Earnings Preview